US 10835505
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
granted A61KA61K31/165A61K31/192
Quick answer
US patent 10835505 (Oral pharmaceutical formulation for weight loss, diabetes and related disorders) held by Aardvark Therapeutics, Inc. expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aardvark Therapeutics, Inc.
- Grant date
- Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/165, A61K31/192, A61K31/365, A61P